NCT04745949 - PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

August 3, 2027

Study Completion Date

August 3, 2027

Conditions

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma

Interventions

DRUG

Brentuximab Vedotin

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin

Given IV

BIOLOGICAL

Nivolumab

Given IV

DRUG

Prednisone

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

BIOLOGICAL

Rituximab

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER